Given the safety profile and T cell-stimulating activity of the recombinant chaperone vaccine targeting melanoma antigen gp100 already established in the phase I clinical trial, our findings may provide a direct path to translating this next-generation chaperone complex vaccine from the laboratory into the clinic. Here, PMEL is linked to melanoma.